In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Demyelinating diseases are a group of disorders of the nervous system that involve loss of the myelin sheath that normally surrounds the neurons. Demyelinating diseases can affect both the central ...

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

Chronic inflammatory demyelinating polyneuropathy (CIPD) can have a substantial impact on patients everyday life and, ...

Lucia Notterpek, Ph.D., professor and senior associate dean for research at the University of Nevada, Reno School of Medicine ...

I foolishly was in a crowded indoor location and got COVID (for the third time). I thought about getting Paxlovid. But I figured, heck, I’m healthy and vaccinated; I’ll just tough it out. This turned ...

Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.